TRAVERE THERAPEUTICSCS INC
TRAVERE THERAPEUTICSCS INC
Aktie · US89422G1076 · TVTX · A2QHYP (XNAS)
Übersicht Finanzkennzahlen
15,21 USD
3,33 % 0,49 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 17:49

Aktuelle Kurse von TRAVERE THERAPEUTICSCS INC

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
TVTX
USD
06.06.2025 17:49
15,21 USD
14,72 USD
+3,33 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
3,33 % 1,26 % -28,96 % -21,64 % -21,64 % 94,25 % -6,52 %

Firmenprofil zu TRAVERE THERAPEUTICSCS INC Aktie

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Investierte Fonds

Folgende Fonds haben in investiert: TRAVERE THERAPEUTICSCS INC investiert:

Fonds
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. in Mio
43,83
Anteil (%)
0,10 %

Unternehmensdaten

Name TRAVERE THERAPEUTICSCS INC
Firma Travere Therapeutics, Inc.
Symbol TVTX
Website https://www.travere.com
Heimatbörse XNAS NASDAQ
WKN A2QHYP
ISIN US89422G1076
Wertpapierart Aktie
Sektor Healthcare
Branche Biotechnology
CEO Dr. Eric M. Dube Ph.D.
Marktkapitalisierung 1 Mrd.
Land Vereinigte Staaten von Amerika
Währung USD
Mitarbeiter 0,4 T
Adresse 3611 Valley Centre Drive, 92130 San Diego
IPO Datum 2012-11-08

Kennungs-Wechsel

Datum Von Zu
19.11.2020 RTRX TVTX

Ticker Symbole

Name Symbol
NASDAQ TVTX

Weitere Aktien

Investoren die TRAVERE THERAPEUTICSCS INC die halten, haben auch folgende Aktien im Depot:
AMGEN INC
AMGEN INC Aktie
AUTODESK INC
AUTODESK INC Aktie
BRIQ PPTS REAL ESTATE
BRIQ PPTS REAL ESTATE Aktie
CISCO SYSTEMS INC
CISCO SYSTEMS INC Aktie
COSTCO WHOLESALE CORP
COSTCO WHOLESALE CORP Aktie
DEXCO INC
DEXCO INC Aktie
HANSAINTERNATIONAL CL. A
HANSAINTERNATIONAL CL. A Fonds
INTEL CORP
INTEL CORP Aktie
INTUITIVE SURGICAL INC
INTUITIVE SURGICAL INC Aktie
Lightwave Logic, Inc. - Common Stock
Lightwave Logic, Inc. - Common Stock Aktie
MICROSOFT CORP
MICROSOFT CORP Aktie
NETFLIX INC
NETFLIX INC Aktie
NUCO CORP
NUCO CORP Aktie
WALGREENS BOOTS ALLIANCE INC
WALGREENS BOOTS ALLIANCE INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025